Share-based Payment Arrangement, Expense of NORTHWEST BIOTHERAPEUTICS INC from 30 Jun 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NORTHWEST BIOTHERAPEUTICS INC quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2011 to 30 Sep 2025.
  • NORTHWEST BIOTHERAPEUTICS INC Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $273,000, a 60% decline year-over-year.
  • NORTHWEST BIOTHERAPEUTICS INC Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,498,000, a 67% decline year-over-year.
  • NORTHWEST BIOTHERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2024 was $3,456,000, a 22% decline from 2023.
  • NORTHWEST BIOTHERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2023 was $4,408,000, a 64% decline from 2022.
  • NORTHWEST BIOTHERAPEUTICS INC annual Share-based Payment Arrangement, Expense for 2022 was $12,298,000, a 21% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NORTHWEST BIOTHERAPEUTICS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,498,000 $273,000 -$416,000 -60% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $1,914,000 $364,000 -$763,000 -68% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $2,677,000 $385,000 -$779,000 -67% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $3,456,000 $476,000 -$1,100,000 -70% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $4,556,000 $689,000 -$933,000 -58% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $5,489,000 $1,127,000 +$850,000 +307% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $4,639,000 $1,164,000 +$231,000 +25% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $4,408,000 $1,576,000 -$981,000 -38% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $5,389,000 $1,622,000 -$1,739,000 -52% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $7,128,000 $277,000 -$5,486,000 -95% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $12,614,000 $933,000 +$316,000 +51% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $12,298,000 $2,557,000 +$1,618,000 +172% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
Q3 2022 $10,680,000 $3,361,000 +$2,098,000 +166% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $8,582,000 $5,763,000 +$2,212,000 +62% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $6,370,000 $617,000 -$9,201,000 -94% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $15,571,000 $939,000 -$11,709,000 -93% 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
Q3 2021 $27,280,000 $1,263,000 -$37,645,000 -97% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $64,925,000 $3,551,000 +$3,516,000 +10046% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $61,409,000 $9,818,000 +$9,454,000 +2597% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $51,955,000 $12,648,000 +$12,390,000 +4802% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $39,565,000 $38,908,000 +$38,336,000 +6702% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $1,229,000 $35,000 -$403,000 -92% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $1,632,000 $364,000 -$189,000 -34% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $1,821,000 $258,000 -$732,000 -74% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
Q3 2019 $2,553,000 $572,000 -$885,000 -61% 01 Jul 2019 30 Sep 2019 10-Q 15 Jan 2021 2020 Q3
Q2 2019 $3,438,000 $438,000 -$11,131,000 -96% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $14,569,000 $553,000 +$283,000 +105% 01 Jan 2019 31 Mar 2019 10-Q 24 Jun 2020 2020 Q1
Q4 2018 $14,286,000 $990,000 01 Oct 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
Q3 2018 $1,457,000 +$1,338,000 +1124% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $11,569,000 +$11,196,000 +3002% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2019 Q2
Q1 2018 $270,000 01 Jan 2018 31 Mar 2018 10-Q 10 May 2019 2019 Q1
Q3 2017 $119,000 01 Jul 2017 30 Sep 2017 10-Q 16 Nov 2018 2018 Q3
Q2 2017 $373,000 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2015 $12,600,000 $6,400,000 +$3,900,000 +156% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2015 2015 Q1
Q4 2014 $8,700,000 $2,600,000 +$2,600,000 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2016 2015 FY
Q3 2014 $6,100,000 $900,000 +$769,000 +587% 01 Jul 2014 30 Sep 2014 10-Q 19 Nov 2014 2014 Q3
Q2 2014 $5,331,000 $2,700,000 +$2,090,000 +343% 01 Apr 2014 30 Jun 2014 10-Q 15 Aug 2014 2014 Q2
Q1 2014 $3,241,000 $2,500,000 +$1,891,000 +311% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2014 2014 Q1
Q4 2013 $1,350,000 $0 -$629,000 -100% 01 Oct 2013 31 Dec 2013 10-K 01 Apr 2014 2013 FY
Q3 2013 $1,979,000 $131,000 -$546,000 -81% 01 Jul 2013 30 Sep 2013 10-Q 15 Nov 2013 2013 Q3
Q2 2013 $2,525,000 $610,000 -$245,000 -29% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2013 2013 Q2
Q1 2013 $2,770,000 $609,000 -$433,000 -42% 01 Jan 2013 31 Mar 2013 10-Q 15 May 2013 2013 Q1
Q4 2012 $3,203,000 $629,000 01 Oct 2012 31 Dec 2012 10-K 01 Apr 2014 2013 FY
Q3 2012 $677,000 -$727,000 -52% 01 Jul 2012 30 Sep 2012 10-Q 15 Nov 2013 2013 Q3
Q2 2012 $855,000 -$4,603,000 -84% 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013 2013 Q2
Q1 2012 $1,042,000 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013 2013 Q1
Q3 2011 $1,404,000 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012 2012 Q3
Q2 2011 $5,458,000 01 Apr 2011 30 Jun 2011 10-Q/A 12 Sep 2012 2012 Q2

NORTHWEST BIOTHERAPEUTICS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,456,000 -$952,000 -22% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $4,408,000 -$7,890,000 -64% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $12,298,000 -$3,273,000 -21% 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024 2023 FY
2021 $15,571,000 -$36,384,000 -70% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
2020 $51,955,000 +$50,134,000 +2753% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $1,821,000 -$12,465,000 -87% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
2018 $14,286,000 +$13,718,000 +2415% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
2017 $568,000 01 Jan 2017 31 Dec 2017 10-K 02 Apr 2019 2018 FY
2015 $2,000,000 -$6,700,000 -77% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2016 2015 FY
2014 $8,700,000 +$7,350,000 +544% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2016 2015 FY
2013 $1,350,000 -$1,853,000 -58% 01 Jan 2013 31 Dec 2013 10-K 01 Apr 2014 2013 FY
2012 $3,203,000 -$5,242,000 -62% 01 Jan 2012 31 Dec 2012 10-K 01 Apr 2014 2013 FY
2011 $8,445,000 01 Jan 2011 31 Dec 2011 10-K 08 Apr 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.